Merck Animal Health Completes Acquisition of Elanco’s Aqua Business

July 18, 2024 Merck Animal Health

As a result of the acquisition, Merck Animal Health now owns innovative products such as CLYNAV®, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease and IMVIXA®, an anti-parasitic sea lice treatment and water treatment products for warm water production, complementing Merck Animal Health’s vaccine portfolio.

Stronger America Through Seafood (SATS) Hosts Fly-In to Advocate for Legislation to Support the Expansion of U.S. Offshore Aquaculture

As demand for sustainable protein rises, aquaculture, which is one of the most sustainable forms of protein production today, has become the fastest growing food production sector globally – producing half of the seafood consumed worldwide. But inefficient federal permitting processes and a lack of regulatory certainty in the U.S. has hindered growth of America’s aquaculture industry. As a result, the U.S. ranks only 17th in aquaculture production with the U.S. aquaculture market valued at $1.5 billion – only 0.6% of the $263 billion global aquaculture market. The U.S. imports up to 80% of its seafood – mainly from Asia and Europe.